Orthofix Medical Inc expected to post a loss of 33 cents a share - Earnings Preview

Orthofix Medical

03/05/2024 16:00

* Orthofix Medical Inc  OFIX.OQ   OFIX.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 7 for
the period ending March 31 2024
    * The Lewisville Texas-based  company is expected to report
a
5.1% increase in revenue to $184.126 million from $175.2 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Orthofix Medical Inc is
for a
loss of 33 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Orthofix
Medical
Inc is $15.00​, above​ its last closing price of $13.24. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.07       -0.08      0.02      Beat    126.2
 Sep. 30 2023  -0.21       -0.21      0.07      Beat    133.5
 Jun. 30 2023  -0.45       -0.47      0.02      Beat    104.2​
 Jan. 1 0001   -0.52       -0.51      -0.10     Beat    80.4
 ​​Dec.        0.34        0.10       0.19      Beat    83.9
 31 2022                                                
 Sep. 30 2022  0.13        0.12       0.13      Beat    11.4​
 Jun. 30 2022  0.10        0.10       0.08      Missed  -20
 Mar. 31 2022  0.10        0.09       -0.10     Missed  -215.4
 This summary was machine generated May 3 at 15:00 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)